Regeneron's Crucial Eylea HD Approval: A Shield Against Potential Biosimilar Competition?
Portfolio Pulse from Vandana Singh
The FDA has approved Regeneron Pharmaceuticals' Eylea HD Injection 8 mg for wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. This approval is seen as a shield against potential biosimilar competition. Truist Securities and BMO Capital remain bullish on Regeneron due to this approval. However, Regeneron is still involved in a lawsuit with Viatris regarding the potential introduction of their Eylea biosimilar. RBC Capital Markets has increased the price target for Regeneron from $820 to $830.
August 21, 2023 | 7:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Roche Holdings' Vabysmo is seen as a competitor to Regeneron's Eylea. However, the approval of Eylea HD by the FDA may reduce the competitive threat posed by Vabysmo.
Roche's Vabysmo is a competitor to Regeneron's Eylea. However, the FDA approval of Eylea HD may reduce the competitive threat posed by Vabysmo, potentially negatively impacting Roche's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Regeneron's Eylea HD approval by the FDA is expected to shield the company against potential biosimilar competition. The company's stock price may see a positive impact due to this approval and the increased price target by RBC Capital Markets.
The FDA approval of Eylea HD is a significant development for Regeneron, potentially protecting it from biosimilar competition. This, coupled with the increased price target by RBC Capital Markets, is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100